Q2 2026 saw 11% constant currency revenue growth for Hexvix/Cysview, driven by strong North American and European performance, and the strategic acquisition of Vesica Health. Adjusted EBITDA margin remained robust at 19%, while regulatory and technological advances are set to expand future market opportunities.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.